Jyothi Devakumar,
Principal Consultant,
Evolvis Consulting, Singapore
Dr. Jyothi Devakumar is currently working as the principal consultant in Evolvis Consulting, a Singapore based company and also participating in creation of an investment fund focused on financing cutting-edge regenerative medicine and anti-aging companies. She most recently worked as the Vice President and Chief Scientific Officer of Nygard Biotech, a company focused on establishing anti-aging solutions using stem cells and their derivatives through a combination of in-house and collaborative research. The focus was to establish quick and efficient pathways to clinical translation of cutting-edge technologies including stem cell based strategies. Nygard Biotech believes in the concept of extending the healthy lifespan with a focus on finding effective solutions to treat and prevent life-threatening age-related disease conditions. Devakumar has more than 10 years of R&D experience, including both academic and commercial aspects of stem cell therapy and drug discovery, having worked in various international settings. Her projects have encompassed technology due diligence and in-licensing of stem cell-related technologies. She has expertise in international regulation of stem cells, hands-on work experience in cGMP, as well as GCP in the design and execution of clinical trials. She obtained her PhD degree in Biotechnology. Subsequently, she performed postdoctoral studies in France in the field of in vivo delivery system with support from EEGID, Government of France. She then worked for several years in the field of drug discovery as one of the leads in an Indian CRO engaging several of the large and mid-sector pharma and biotech companies in both Europe and US. She serves on the editorial board of CellR4 and the scientific advisory board of BGI Health.
|
|
|